Vistagen Therapeutics, Inc.
Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update
Advancing potential to execute Phase 3 development plan for fasedienol in social anxiety disorder following constructive FDA feedback, with…